Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 10, 2025 05:00 ET | Source: XL-protein GmbH

XL-protein grants worldwide license to Grifols to develop a biopharmaceutical using PASylation® technology

Freising, Germany, June 10, 2025 — XL-protein GmbH, a pioneer in the area of biopolymers for pharmacokinetic optimization, announced today that it has entered into a worldwide License, Development and...
January 16, 2025 16:05 ET | Source: Adeia Inc.

Adeia to Release Fourth Quarter 2024 Financial Results on February 18, 2025

SAN JOSE, Calif., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Adeia Inc. (Nasdaq: ADEA) will announce its financial results for the fourth quarter ended December 31, 2024, on Tuesday, February 18, 2025,...
November 07, 2024 16:12 ET | Source: Adeia Inc.

Adeia Announces Third Quarter 2024 Financial Results

Signed 7 deals across multiple verticals in the third quarterBoard increased share repurchase authorization up to $200 millionFiled patent infringement litigation against DisneySigned a new...
October 07, 2024 08:00 ET | Source: Connexa Sports Technologies Inc.

Yuanyu Enterprise Management announces entry into an exclusive license agreement for its innovative matchmaking technology covering the UK and Europe

UK-based Eternity Technology Limited agrees to license Yuanyu’s matchmaking services for the emerging Love & Marriage sector.Agreement to generate more than $19 million in license income for YYEM...
September 26, 2024 07:30 ET | Source: Evaxion Biotech

Evaxion significantly expands vaccine development collaboration with MSD

Agreement provides MSD with options to license Evaxion’s preclinical, AI-designed vaccine candidates EVX-B2 and EVX-B3Evaxion will host a conference call and webcast to discuss the agreement on...
September 12, 2024 05:00 ET | Source: ITM Isotope Technologies Munich SE

ITM Obtains Exclusive Worldwide License from Debiopharm for CA IX-Targeted Peptide-based Radiopharmaceutical Programs Targeting Solid Tumors

ITM gains exclusive global development and commercialization rights to Debiopharm’s first-in-class, peptide-based theranostic pair which combines therapeutic compound, Debio 0228 ([177Lu]Lu-DPI-4452)...
July 08, 2024 16:05 ET | Source: Adeia Inc.

Adeia Renews Long-Term IP License Agreement with Liberty Global

Adeia Renews Long-Term IP License Agreement with Liberty Global
July 01, 2024 16:05 ET | Source: Adeia Inc.

Adeia Enters into Multi-Year IP License Agreement with X Corp.

Adeia Enters into Multi-Year IP License Agreement with X Corp.
June 13, 2024 07:00 ET | Source: BioRestorative Therapies, Inc

BioRestorative Therapies in Substantive Discussions for Potential License Agreement for ThermoStem® Metabolic Disease Program

- Brown adipose derived stem cells with brown adipogenic potential would represent a new modality for the treatment of obesity and related metabolic disorders – - ThermoStem® is an off-the-shelf...
January 30, 2024 12:00 ET | Source: Autonomix Medical, Inc.

Autonomix Medical, Inc. Completes $8,000,000 Transaction for Exclusive Worldwide Rights to Technology for Cardiology Field Use – Over 100 patents in portfolio

Autonomix now wholly owns development and commercialization rights to its technology in all indications Re-acquisition broadens Autonomix’s development and strategic opportunities THE WOODLANDS,...